

What is claimed is:

1. A CR-50 epitope region polypeptide of Reelin protein, which comprises a CR-50 antibody recognition site of Reelin protein, but comprises neither a F-spondin domain nor a repeat site.

2. The CR-50 epitope region polypeptide of Reelin protein according to claim 1, which is derived from a mouse.

3. A polypeptide selected from the group consisting of:

(a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2; and

(b) a polypeptide capable of binding to CR-50 antibody, which comprises deletion, substitution or addition of one or more amino acids in the amino acid sequence shown in SEQ ID NO: 2.

4. A polynucleotide encoding the polypeptide according to any one of claims 1 to 3.

5. A polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO: 1;

(b) a polynucleotide encoding a polypeptide capable of binding to CR-50 antibody, which comprises deletion, substitution or addition of one or more nucleotides in the nucleotide sequence shown in SEQ ID NO: 1; and

(c) a polynucleotide comprising a degenerate nucleotide sequence of polynucleotide (a) or (b).

6. An expression vector comprising the polynucleotide according to claim 4 or 5.

7. A host cell transfected with the expression vector according to claim 6.
8. A method for producing the polypeptide according to any one of claims 1 to 3, which comprises culturing the host cell according to claim 7.
9. A method for stimulating the assembly of Reelin protein molecules, which comprises adding the polypeptide according to any one of claims 1 to 3 or the polynucleotide according to claim 4 or 5.
10. A composition for stimulating the assembly of Reelin protein molecules, which comprises the polypeptide according to any one of claims 1 to 3 or the polynucleotide according to claim 4 or 5.
11. A pharmaceutical composition for diagnosis and/or treatment of diseases resulting from abnormally positioned neurons, which comprises the polypeptide according to any one of claims 1 to 3 or the polynucleotide according to claim 4 or 5.